Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
PRINCETON, N.J., Oct. 02, 2017 -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday, October 10, 2017 in New York City.
Members of Agile’s executive team will review clinical data and discuss the commercialization plan for Twirla®, the company's lead investigational once weekly low-dose prescription contraceptive patch. Management will be joined by leading external experts who will provide clinical perspectives on Twirla, as well as regulatory and market access insights into today’s contraceptive marketplace.
To access the live webcast, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. A replay will be available on the company’s website.
| Event Details | |
| Date: | Tuesday, October 10, 2017 |
| Time: | 11:00 a.m. – 1:30 p.m. ET |
| Location: | New York City |
| Speakers will include: | |
| Alfred Altomari | Chairman and CEO, Agile Therapeutics |
| Elizabeth Garner, M.D., MPH | Senior Vice President, Chief Medical Officer, Agile Therapeutics |
| Renee Selman | Chief Commercial Officer, Agile Therapeutics |
| Robin Kroll, M.D., FACOG | Director, Seattle Women’s: Health, Research, Gynecology; |
| SECURE Trial Investigator | |
| David J. Portman, M.D., FACOG | Director Emeritus, Columbus Center for Women’s Health |
| Research; CEO and Chief Medical Officer, Sermonix | |
| Pharmaceuticals | |
| Minnie Baylor-Henry, J.D., R.Ph | Executive Partner, YourEncore; Former Director, Division of |
| Drug Marketing, Advertising and Communications (DDMAC), | |
| Food and Drug Administration; Former Worldwide Vice | |
| President, Regulatory Affairs, Johnson & Johnson | |
| Adaeze Enekwechi, PhD, MPP | VP, McDermottPlus Consulting in Washington,D.C.; Former |
| Associate Director for Health Programs, White House Office of | |
| Management and Budget under President Obama | |
Analysts and institutional investors seeking more information about this event should contact Matt Ventimigila by phone or email: [email protected], or 212-599-1265.
About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. The company may occasionally disseminate material, nonpublic information on the company website.
Follow Agile on Twitter: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.
About Twirla®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.
Contact:
Mary Coleman
Agile Therapeutics, Inc.
609-356-1921
